Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

A neonatal murine model for evaluation of enterovirus E HY12 virus infection and pathogenicity.

Gai X, Zhang Q, Lu H, Yang Z, Zhu L, Li X, Wang X.

PLoS One. 2018 Feb 15;13(2):e0193155. doi: 10.1371/journal.pone.0193155. eCollection 2018.

2.

Risk factors for death in children with critical and severe hand-foot-and-mouth disease in Chongqing, China: An observational study.

Zheng G, Cao J, Yu J, Zhang Z, Liu Q, Chen J.

Medicine (Baltimore). 2017 Dec;96(49):e8934. doi: 10.1097/MD.0000000000008934.

3.

A mutation-resistant deoxyribozyme OR gate for highly selective detection of viral nucleic acids.

Kamar O, Sun SC, Lin CH, Chung WY, Lee MS, Liao YC, Kolpashchikov DM, Chuang MC.

Chem Commun (Camb). 2017 Sep 21;53(76):10592-10595. doi: 10.1039/c7cc05576e.

PMID:
28900642
4.

Prevalence of enteroviruses in healthy populations and excretion of pathogens in patients with hand, foot, and mouth disease in a highly endemic area of southwest China.

Wu Q, Fu X, Jiang L, Yang R, Cun J, Zhou X, Zhou Y, Xiang Y, Gu W, Fan J, Li H, Xu W.

PLoS One. 2017 Jul 13;12(7):e0181234. doi: 10.1371/journal.pone.0181234. eCollection 2017.

5.

Phylogeography of Coxsackievirus A16 Reveals Global Transmission Pathways and Recent Emergence and Spread of a Recombinant Genogroup.

Hassel C, Mirand A, Farkas A, Diedrich S, Huemer HP, Peigue-Lafeuille H, Archimbaud C, Henquell C, Bailly JL; HFMD French Study Network.

J Virol. 2017 Aug 24;91(18). pii: e00630-17. doi: 10.1128/JVI.00630-17. Print 2017 Sep 15.

6.

Epidemiological characterizations, pathogen spectrum and molecular characteristics of Coxsackievirus A16 from patients with HFMD in Yantai, Shandong, China between 2011 and 2015.

Sun Z, Zhang G, Guo P, Liu J, Gao Q, Xu X, Gong L.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1831-1838. doi: 10.1080/21645515.2017.1318233. Epub 2017 May 24.

PMID:
28537484
7.

A novel enterovirus species identified from severe diarrheal goats.

Wang M, He J, Lu H, Liu Y, Deng Y, Zhu L, Guo C, Tu C, Wang X.

PLoS One. 2017 Apr 4;12(4):e0174600. doi: 10.1371/journal.pone.0174600. eCollection 2017.

9.

The Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine Development.

Chang PC, Chen SC, Chen KT.

Int J Environ Res Public Health. 2016 Sep 9;13(9). pii: E890. doi: 10.3390/ijerph13090890. Review.

10.

Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China.

Wang JX, Zhu SL, Wang J, Lin Y, Pei YW, Sun DP, Zhang Y, Wang XJ, Xu WB, Ding SJ.

PLoS One. 2016 Sep 9;11(9):e0162373. doi: 10.1371/journal.pone.0162373. eCollection 2016.

11.

Characterization of VP1 sequence of Coxsackievirus A16 isolates by Bayesian evolutionary method.

Zhao G, Zhang X, Wang C, Wang G, Li F.

Virol J. 2016 Jul 28;13:130. doi: 10.1186/s12985-016-0578-3.

12.

Development and evaluation of a non-ribosomal random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot and mouth disease pathogens.

Nguyen AT, Tran TT, Hoang VM, Nghiem NM, Le NN, Le TT, Phan QT, Truong KH, Le NN, Ho VL, Do VC, Ha TM, Nguyen HT, Nguyen CV, Thwaites G, van Doorn HR, Le TV.

Virol J. 2016 Jul 7;13:125. doi: 10.1186/s12985-016-0580-9.

13.

Clinical and Associated Immunological Manifestations of HFMD Caused by Different Viral Infections in Children.

Wang J, Pu J, Liu L, Che Y, Liao Y, Wang L, Guo L, Feng M, Liang Y, Fan S, Cai L, Zhang Y, Li Q.

Glob Pediatr Health. 2016 May 27;3:2333794X16643723. doi: 10.1177/2333794X16643723. eCollection 2016.

14.

Molecular epidemiology of human coxsackievirus A16 strains.

Yu W, Xu H, Yin C.

Biomed Rep. 2016 Jun;4(6):761-764. Epub 2016 Apr 22.

15.

Protein microarray-mediated detection of antienterovirus antibodies in serum.

Zhang A, Xiu B, Zhang H, Li N.

J Int Med Res. 2016 Apr;44(2):287-96. doi: 10.1177/0300060515604981. Epub 2016 Feb 1.

16.

Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.

Wu CY, Lin YW, Kuo CH, Liu WH, Tai HF, Pan CH, Chen YT, Hsiao PW, Chan CH, Chang CC, Liu CC, Chow YH, Chen JR.

PLoS One. 2015 Aug 19;10(8):e0136420. doi: 10.1371/journal.pone.0136420. eCollection 2015.

17.

Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice.

Chang J, Li J, Liu X, Liu G, Yang J, Wei W, Zhang W, Yu XF.

BMC Microbiol. 2015 Jul 15;15:139. doi: 10.1186/s12866-015-0474-9.

18.

The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Mao Q, Wang Y, Shao J, Ying Z, Gao F, Yao X, Li C, Ye Q, Xu M, Li R, Zhu F, Liang Z.

Hum Vaccin Immunother. 2015;11(11):2723-33. doi: 10.1080/21645515.2015.1011975. Epub 2015 Feb 25.

19.

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, Fan P, An D, Yang P, Lu J, Lv X, Sun B, Xu F, Kong W, Jiang C.

Hum Vaccin Immunother. 2014;10(10):2885-95. doi: 10.4161/hv.29823.

20.

Supplemental Content

Support Center